Interventions of Interest:
- etranacogene dezaparvovec (Hemgenix, CSL Behring)
- valoctocogene roxaparvovec (Roctavian ™; BioMarin)
ICER reviewed valoctocogene roxaparvovec for hemophilia A in 2020 (Valoctocogene Roxaparvovec and Emicizumab for Hemophilia A without Inhibitors: Effectiveness and Value). In this review, the two interventions will be considered separately as if we were performing two independent reviews in two different populations.